SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
508 37 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Min  Hr  Day  Wk  Mon  Yr  3 Yr  Log
NKTR 22.48-5.9%Jan 17 4:00 PM EST
Top Headlines - Nektar Therapeutics
BUZZ-U.S. STOCKS ON THE MOVE-Target, PG&E, Nektar Therapeutics, Beyond Meat last Wednesday
Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plumm last Wednesday
Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock last Wednesday
How An FDA Committee Pulled The Rug Out From This Highflying Biotech last Wednesday
Why Nektar Therapeutics Stock Is Sinking Today last Wednesday
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
508NKTR181, to abort was the only *right* option. ir.nektar.comMiljenko Zuanic-last Wednesday
507I commented on the JPM Q&A session, including the "Competing CombinatioDewDiligence_on_SI-last Tuesday
506NKTR-BMY bempeg (214) amendment: <On January 9, 2020, Nektar Therapeutics, a Miljenko Zuanic1January 10
505MILs? There are too many acronyms already!DewDiligence_on_SI-12/19/2019
504<The FDA remains committed to addressing this national crisis on all fronts, Miljenko Zuanic-12/19/2019
503WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-MyerMiljenko Zuanic-12/19/2019
502Sanofi going after Synthrox (THOR), IL2 player. sanofi.comMiljenko Zuanic-12/9/2019
501RE: NKTR-255 Early, so it is on active screen: nektar.comMiljenko Zuanic-11/10/2019
500RE: NKTR358 (@ACR) PR: finance.yahoo.com Poster: nektar.com < subcutaneous doMiljenko Zuanic-11/10/2019
499Twitter is full of BS members. For no good reason I am blocked 50% of the timesMiljenko Zuanic111/10/2019
498Is there opening for IO-triple regime (PD1 + CTLA-4 + IL2), and chemo-sparing???Miljenko Zuanic-10/22/2019
497finance.yahoo.com Stephen Doberstein (chief-R&D, 181-inventor) is gently pMiljenko Zuanic-10/1/2019
496secfilings.nasdaq.com Why took him so long? Well, better ever than never...Miljenko Zuanic-9/10/2019
495Thanks Julius for complete institutions ownership report. I was rounding INVESCOMiljenko Zuanic-9/7/2019
494 Holder Shares Date Reported % Out Value Invesco Ltd. 23,343,019 Jun 29, 201Julius Wong-9/7/2019
493I did not commented early on this,... for 2Q INVESCO Ltd increased position by 2Miljenko Zuanic-9/7/2019
492Most likely there will be extension of the PDUFA, 3-6 months, and Adcom is very Miljenko Zuanic18/28/2019
491I guess technically I am not accurate in them saying it won't be met but howghmm-8/28/2019
490So, it appears there is no 181 CRL and path to approval is intact. MrM need updMiljenko Zuanic-8/28/2019
489FWIW they already announced PDUFA won't be met. That was CFO and he exerciseghmm-8/28/2019
488Unbelievable—-the CEO dumps another 30,000 shares four days before the FDA is scArthur Radley-8/26/2019
487What a waste of the options! SUCKERS!Miljenko Zuanic-8/19/2019
486CFO nets another $250;000.00 by flipping a option conversion into shares and selArthur Radley-8/17/2019
485Ah, well maybe they can amend that suit. Something to keep an eye on. Whatevertuck-8/9/2019
484<Mildly surprised no class action suit has been filed yet.> "On OctobMiljenko Zuanic-8/9/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):